EP2867375A4 - USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER - Google Patents

USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Info

Publication number: EP2867375A4
Authority: EP; European Patent Office
Prior art keywords: markers; diagnosis; treatment; prostate cancer; prostate
Prior art date: 2012-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP13809780.3A

Other languages

German (de)

French (fr)

Other versions

EP2867375B1 (en

EP2867375A1 (en

Inventor

Niven Rajin Narain

Rangaprasad Sarangarajan

Vivek K Vishnudas

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

BERG LLC

Original Assignee

BERG LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-27

Filing date

2013-06-27

Publication date

2016-06-01

2013-06-27 Application filed by BERG LLC filed Critical BERG LLC

2015-05-06 Publication of EP2867375A1 publication Critical patent/EP2867375A1/en

2016-06-01 Publication of EP2867375A4 publication Critical patent/EP2867375A4/en

2019-02-27 Application granted granted Critical

2019-02-27 Publication of EP2867375B1 publication Critical patent/EP2867375B1/en

Status Active legal-status Critical Current

2033-06-27 Anticipated expiration legal-status Critical

Links

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP13809780.3A 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer Active EP2867375B1 (en)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US201261665201P	2012-06-27	2012-06-27
US201261672090P	2012-07-16	2012-07-16
US201261673094P	2012-07-18	2012-07-18
US201261702523P	2012-09-18	2012-09-18
US201261718080P	2012-10-24	2012-10-24
US201261718081P	2012-10-24	2012-10-24
US201261718064P	2012-10-24	2012-10-24
PCT/US2013/048373 WO2014004931A1 (en)	2012-06-27	2013-06-27	Use of markers in the diagnosis and treatment of prostate cancer

Publications (3)

Publication Number	Publication Date
EP2867375A1 EP2867375A1 (en)	2015-05-06
EP2867375A4 true EP2867375A4 (en)	2016-06-01
EP2867375B1 EP2867375B1 (en)	2019-02-27

Family

ID=49783880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13809780.3A Active EP2867375B1 (en)	2012-06-27	2013-06-27	Use of markers in the diagnosis and treatment of prostate cancer

Country Status (15)

Country	Link
US (3)	US20140038838A1 (en)
EP (1)	EP2867375B1 (en)
JP (2)	JP6352909B2 (en)
KR (1)	KR20150023904A (en)
CN (1)	CN104583422A (en)
AU (1)	AU2013284448B2 (en)
BR (1)	BR112014032728A2 (en)
CA (1)	CA2877721A1 (en)
EA (1)	EA201492284A1 (en)
ES (1)	ES2720763T3 (en)
IL (1)	IL236482A0 (en)
MX (1)	MX360236B (en)
NZ (1)	NZ703411A (en)
SG (1)	SG11201408651TA (en)
WO (1)	WO2014004931A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY193914A (en)	2012-03-05	2022-11-01	Oy Arctic Partners Ab	Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
AU2015215008B2 (en) *	2014-02-05	2019-11-28	Fujirebio Diagnostics Ab	Composition and method for detecting malignant neoplastic disease
US12326453B2 (en)	2014-03-28	2025-06-10	Opko Diagnostics, Llc	Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (en)	2014-03-28	2023-11-27	Opko Diagnostics Llc	COMPOSITIONS AND METHODS RELATED TO THE DIAGNOSIS OF PROSTATE CANCER
US10539566B2 (en) *	2014-12-08	2020-01-21	Berg Llc	Use of markers including filamin A in the diagnosis and treatment of prostate cancer
WO2016160545A1 (en)	2015-03-27	2016-10-06	Opko Diagnostics, Llc	Prostate antigen standards and uses thereof
EP3463450A4 (en) *	2016-06-03	2020-07-29	Etubics Corporation	COMPOSITIONS AND METHODS FOR TUMOR VACCINATION WITH PROSTATE CANCER-ASSOCIATED ANTIGENS
EP3490677A4 (en) *	2016-07-07	2020-05-13	Berg LLC	LIPID, PROTEIN AND METABOLIC MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
WO2018189292A1 (en) *	2017-04-13	2018-10-18	Institut National De La Sante Et De La Recherche Medicale	Biomarkers of castration-resistant prostatic cells
KR102405789B1 (en) *	2018-08-24	2022-06-07	고려대학교 세종산학협력단	A biomaker composition for diagnosing prostate cancer comprising a kynurenine pathway metabolome
CN109608536B (en) *	2018-12-12	2020-09-15	深圳市龙华区人民医院	Epitope polypeptide CD44-P3 based on prostate cancer stem cell marker CD44 and application thereof
CN109608537B (en) *	2018-12-12	2020-09-15	深圳市龙华区人民医院	Epitope polypeptide CD44-P2 based on prostate cancer stem cell marker CD44 and application thereof
KR102497196B1 (en) *	2020-09-08	2023-02-07	(주)유로테크	A method to calculate a diagnostic score for a prostate cancer and use thereof
CN114134223B (en) *	2021-12-02	2022-10-11	青岛市中心血站	Blood detection kit for hepatitis C virus-related liver fibrosis
CN114460297A (en) *	2022-01-17	2022-05-10	珠海中科先进技术研究院有限公司	Immunofluorescence kit for detecting circulating prostate epithelial cells in blood and using method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004076614A2 (en) *	2003-02-27	2004-09-10	Bernd Hinzmann	Human nucleic acid sequences obtained from prostatic carcinomas
WO2007071947A1 (en) *	2005-12-19	2007-06-28	University Of Hull	Cancer screening test
WO2008121307A2 (en) *	2007-03-28	2008-10-09	Cell Genesys, Inc.	Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US20090215636A1 (en) *	2005-05-25	2009-08-27	Krizman David B	Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2011040532A1 (en) *	2009-10-02	2011-04-07	学校法人久留米大学	Method for predicting therapeutic effect of immunotherapy on cancer patient and/or prognosis after immunotherapy, and gene set and kit to be used therein
US20110236903A1 (en) *	2008-12-04	2011-09-29	Mcclelland Michael	Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2011149402A2 (en) *	2010-05-27	2011-12-01	Atlas Antibodies Ab	Prostate cancer biomarkers
WO2012021969A1 (en) *	2010-08-16	2012-02-23	Mount Sinai Hospital	Markers of the male urogenital tract

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3942999C2 (en)	1989-12-27	1997-12-18	Progen Biotechnik Gmbh	Procedure for the detection of malignant diseases
DE4208422A1 (en)	1992-03-16	1993-09-30	Boehringer Mannheim Gmbh	Method for the detection of micrometastases of ectodermal or endodermal tumors
DE69739909D1 (en)	1996-03-26	2010-07-29	Michael S Kopreski	METHODS USED IN PLASMA OR SERUM EXTRACTED EXTRACELLURAE RNA FOR DIAGNOSIS MONITORING OR EVALUATION OF CANCER
US6107103A (en) *	1996-10-15	2000-08-22	Procyon Bropharma Inc.	Assay for PSP94 protein
WO1999014372A1 (en)	1997-09-15	1999-03-25	Abbott Laboratories	Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en)	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
JP2002527489A (en)	1998-10-22	2002-08-27	キュラゲンコーポレイション	Predictive and therapeutic genes and proteins for kidney and related diseases
CA2702148C (en)	1999-01-06	2014-03-04	Genenews Inc.	Method of profiling gene expression in a human subject having an infectious disease
US8410248B2 (en)	1999-03-12	2013-04-02	Human Genome Sciences Inc.	HWBAO62 polypeptides
US7368527B2 (en)	1999-03-12	2008-05-06	Human Genome Sciences, Inc.	HADDE71 polypeptides
CA2404431C (en)	2000-03-27	2011-06-07	Thomas Jefferson University	Guanylyl cyclase c in the detection of stomach and esophageal cancers
WO2002014500A2 (en)	2000-08-16	2002-02-21	Chiron Corporation	Human genes and gene expression products
WO2002060317A2 (en)	2001-01-30	2002-08-08	Corixa Corporation	Compositions and methods for the therapy and diagnosis of pancreatic cancer
ATE429511T1 (en)	2001-03-01	2009-05-15	Epigenomics Ag	METHOD FOR DEVELOPING GENE SETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES BASED ON THE EXPRESSION AND METHYLATION STATUS OF THE GENES
ES2374311T3 (en)	2002-03-13	2012-02-15	Genomic Health, Inc.	OBTAINING PROFILE OF GENE EXPRESSION IN BIOPSIATED TUMOR FABRICS.
US20040029151A1 (en)	2002-04-09	2004-02-12	Affymetrix, Inc.	Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2003097878A1 (en)	2002-05-21	2003-11-27	Sysmex Corporation	Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
CA2499843A1 (en)	2002-09-25	2004-04-08	Genentech, Inc.	Novel compositions and methods for the treatment of psoriasis
US20050259483A1 (en)	2002-09-30	2005-11-24	Oncotherapy Science, Inc.	Genes and polypeptides relating to prostate cancers
US20040109863A1 (en) *	2002-12-04	2004-06-10	Peter Emtage	Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (en)	2002-12-19	2004-07-08	Ivonex Gmbh	separation process
WO2004058052A2 (en)	2002-12-20	2004-07-15	Applera Corporation	Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
CA2519630A1 (en)	2003-03-20	2004-10-07	Dana-Farber Cancer Institute, Inc.	Gene expression in breast cancer
AU2004248120B2 (en)	2003-05-28	2009-04-23	Genomic Health, Inc.	Gene expression markers for predicting response to chemotherapy
US20060019256A1 (en)	2003-06-09	2006-01-26	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en)	2003-07-14	2007-03-01	Mayo Foundation For Medical Education And Research	Methods and compositions for diagnosis, staging and prognosis of prostate cancer
WO2005012875A2 (en)	2003-07-29	2005-02-10	Bristol-Myers Squibb Company	Biomarkers of cyclin-dependent kinase modulation
EP1522594A3 (en)	2003-10-06	2005-06-22	Bayer HealthCare AG	Methods and kits for investigating cancer
ITPD20030264A1 (en)	2003-10-30	2005-04-30	Xeptagen Spa	HIGHLY SPECIFIC DIAGNOSIS METHOD FOR NEOPLASIA
CN1743849A (en)	2004-09-03	2006-03-08	上海透景生命科技有限公司	Multi tumour tag parallel detecting method and kit
US20060057127A1 (en)	2004-09-10	2006-03-16	Pocheng Liu	Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en)	2004-09-17	2006-03-23	Ozge Alper	Methods and compositions for diagnosing neoplastic disease
EP1815021A2 (en)	2004-11-03	2007-08-08	Almac Diagnostics Limited	Transcriptome microarray technology and methods of using the same
US8383357B2 (en)	2005-03-16	2013-02-26	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CA2601157A1 (en)	2005-03-16	2006-09-28	Osi Pharmaceuticals, Inc.	Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7608413B1 (en)	2005-03-25	2009-10-27	Celera Corporation	Kidney disease targets and uses thereof
EP1870455A4 (en)	2005-03-31	2010-01-20	Two Cells Co Ltd	Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
CA2608359A1 (en)	2005-05-13	2006-11-23	Duke University	Gene expression signatures for oncogenic pathway deregulation
WO2006127860A2 (en)	2005-05-25	2006-11-30	Expression Pathology, Inc.	Multiplex method for increased proteomic coverage from histopathologically processed biological samples using liquid tissue preparations
AU2006259583A1 (en) *	2005-06-13	2006-12-28	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en)	2005-06-13	2007-05-03	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
EP1734118A1 (en)	2005-06-15	2006-12-20	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en)	2005-09-16	2010-11-30	Celera Corporation	Colon disease targets and uses thereof
EP1938104A2 (en)	2005-10-17	2008-07-02	Institute for Systems Biology	Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en)	2005-10-31	2007-09-20	Clarke Michael F	Genetic characterization and prognostic significance of cancer stem cells in cancer
US20070122856A1 (en)	2005-11-10	2007-05-31	Aurelium Biopharma Inc.	Tissue diagnostics for ovarian cancer
US20070231822A1 (en)	2006-02-28	2007-10-04	Michael Mitas	Methods for the detection and treatment of cancer
JP4968577B2 (en)	2006-04-11	2012-07-04	エフ．ホフマン−ラロシュアーゲー	Rapid measurement method of cytokeratin 19 (CK19) mRNA, and primer and probe therefor
US20080003624A1 (en)	2006-06-13	2008-01-03	Sysmex Corporation	Cancer metastasis determination method
WO2008013989A2 (en)	2006-07-27	2008-01-31	Cell Genesys, Inc.	Methods and compositions for identifying a cellular immune response against prostate cancer
AU2007284651B2 (en)	2006-08-09	2014-03-20	Institute For Systems Biology	Organ-specific proteins and methods of their use
US8642349B1 (en)	2006-08-11	2014-02-04	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Artificial neural network proteomic tumor classification
US8748108B2 (en)	2006-09-05	2014-06-10	Abbvie Inc.	Biomarkers for identifying patient classes
WO2008029251A2 (en)	2006-09-07	2008-03-13	Universitatsklinikum Hamburg-Eppendorf	Method for the detection of cancerous epithelial cells using released cytokeratins as markers for said cells
WO2008079269A2 (en)	2006-12-19	2008-07-03	Genego, Inc.	Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
CA2679664C (en) *	2007-03-02	2017-04-25	Cell Genesys, Inc.	Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US20090081659A1 (en)	2007-03-07	2009-03-26	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2559771A3 (en)	2007-05-17	2013-06-12	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en)	2007-06-01	2009-09-03	Anita Lim Hong	Caspase-cleavage anti-keratin antibodies for detection of apoptosis
EP2201134B1 (en)	2007-09-19	2018-11-21	The Research Foundation of State University of New York	Gene expression signatures in enriched tumor cell samples
WO2009045389A2 (en)	2007-10-03	2009-04-09	Osi Pharmaceuticals, Inc.	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en)	2007-10-19	2009-04-23	Duke University	Predicting responsiveness to cancer therapeutics
CN101896818B (en)	2007-12-10	2016-01-20	霍夫曼-拉罗奇有限公司	Seprase as a marker of cancer
KR101810799B1 (en)	2008-02-01	2017-12-19	더 제너럴 하스피탈 코포레이션	Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8008032B2 (en)	2008-02-25	2011-08-30	Cellective Dx Corporation	Tagged ligands for enrichment of rare analytes from a mixed sample
AU2009270851A1 (en)	2008-07-16	2010-01-21	Dana-Farber Cancer Institute, Inc.	Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
WO2010011642A2 (en)	2008-07-21	2010-01-28	The Trustees Of The University Of Pennsylvania	Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en)	2008-10-10	2010-04-21	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
IT1391619B1 (en)	2008-11-04	2012-01-11	Silicon Biosystems Spa	METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
JP5172020B2 (en)	2008-11-12	2013-03-27	エフ．ホフマン−ラロシュアーゲー	PACAP as a marker for cancer
CA2747942C (en)	2008-12-22	2016-12-06	F. Hoffmann-La Roche Ag	Armet as a marker for cancer
JP2012519170A (en)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	INSITU method for monitoring EMT status of tumor cells in vivo
JP2012100536A (en)	2009-03-02	2012-05-31	Genescience Co Ltd	Genetic testing method for cancer by analysis of expression of cancer-relating gene utilizing monocyte contained in blood sample
EP2403877B1 (en)	2009-03-06	2015-05-06	Klaus Tschira Stiftung GgmbH	Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
US20120100538A1 (en)	2009-03-24	2012-04-26	Biocept, Inc.	Devices and methods of cell capture and analysis
US10815517B2 (en)	2009-04-28	2020-10-27	Roche Diagnostics Operations, Inc.	Use of DPPIV/seprase as a marker for cancer
US9456558B2 (en)	2009-10-29	2016-10-04	King Kutter, Inc.	Stump cutter
EP2335838B1 (en)	2009-12-18	2012-09-26	Deutsche Post AG	Sorting system and method using a portable device
US20130095503A1 (en)	2010-01-05	2013-04-18	University Of Cincinnati	Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en)	2010-01-19	2011-07-21	Predictive Biosciences, Inc.	Antibodies and methods of diagnosing diseases
JP2013526852A (en)	2010-04-06	2013-06-27	カリスライフサイエンシズルクセンブルクホールディングス	Circulating biomarkers for disease
US8664472B2 (en)	2010-04-28	2014-03-04	Sesaco Corporation	Pygmy sesame plants for mechanical harvesting
US8557777B2 (en)	2010-07-09	2013-10-15	The Board Of Trustees Of The University Of Illinois	Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
WO2012006634A2 (en)	2010-07-09	2012-01-12	The Board Of Trustees Of The University Of Illiniois	Prostate specific antigen (psa) peptide therapy
US20130217647A1 (en) *	2010-07-28	2013-08-22	Metabolon, Inc.	Biomarkers for Prostate Cancer and Methods Using the Same
CA2808417A1 (en) *	2010-08-18	2012-02-23	Caris Life Sciences Luxembourg Holdings, S.A.R.L.	Circulating biomarkers for disease
WO2012031008A2 (en)	2010-08-31	2012-03-08	The General Hospital Corporation	Cancer-related biological materials in microvesicles
CN106706914B (en)	2010-09-09	2018-10-19	北京同为时代生物技术有限公司	Blood markers object for diagnosing epitheliogenic cancerg and monoclonal antibody
CN103384824B (en)	2010-12-06	2016-02-03	Thd股份公司	Cancer diagnostic methods and uses thereof
AU2011349101A1 (en)	2010-12-24	2013-05-02	Map Diagnostics Pty Ltd	Selective reaction monitoring (SRM) derived protein profiles for cancer and other pathologic entities
WO2012101283A1 (en)	2011-01-28	2012-08-02	Biosystems International Sas	Combinatorial biomarkers for clinical applications in lung cancer patient management
WO2012116248A1 (en)	2011-02-24	2012-08-30	Massachusetts Institute Of Technology	ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
KR101320633B1 (en)	2011-05-25	2013-10-30	엠앤디 (주)	Method of providing information for diagnosis of cancer using quantitative realtime PCR and diagnostic kit comprising thereof
WO2012135397A2 (en)	2011-03-29	2012-10-04	Lisanti Michael P	Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US20130022974A1 (en)	2011-06-17	2013-01-24	The Regents Of The University Of Michigan	Dna methylation profiles in cancer
EP2551673B1 (en)	2011-07-26	2016-01-20	Universidad de Salamanca	Methods for the detection of cancer infiltration of the central nervous system
KR20140067001A (en)	2011-08-08	2014-06-03	카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘.	Biomarker compositions and methods
WO2013039477A1 (en)	2011-09-12	2013-03-21	University Of South Alabama	Non-invasive methods of detecting target molecules
US20150152474A1 (en)	2012-03-09	2015-06-04	Caris Life Sciences Switzerland Holdings Gmbh	Biomarker compositions and methods
HK1208470A1 (en)	2012-03-29	2016-03-04	Biogen Ma Inc.	Biomarkers for use in integrin therapy applications
US20130317083A1 (en)	2012-05-04	2013-11-28	Thomas Jefferson University	Non-coding transcripts for determination of cellular states
TWI468519B (en)	2012-09-05	2015-01-11	Univ China Medical	Methods of detecting squamous cell carcinoma in vitro
US20150226744A1 (en)	2012-09-17	2015-08-13	Ait Austrian Institute Of Technology Gmbh	Colon Cancer Diagnostic Method and Means
US9201061B2 (en)	2013-02-26	2015-12-01	Industry-University Cooperation Foundation Hanyang University	KRT19 stabilizing HER2 and use thereof
EP2972375A2 (en)	2013-03-13	2016-01-20	Creatics LLC	Methods and compositions for detecting pancreatic cancer
SE538211C2 (en)	2013-04-05	2016-04-05	Idl Biotech Ab	Method for detecting cytokeratin 8, 18 and / or 19 and / or soluble fragments thereof
US20150079590A1 (en)	2013-09-18	2015-03-19	Beth Israel Deaconess Medical Center, Inc.	Characterization and analysis of the composition and dynamics of the mammalian riboproteome
EP3047270A4 (en)	2013-09-20	2017-07-19	Astute Medical, Inc.	Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain

2013
- 2013-06-27 CA CA2877721A patent/CA2877721A1/en not_active Abandoned
- 2013-06-27 MX MX2015000008A patent/MX360236B/en active IP Right Grant
- 2013-06-27 ES ES13809780T patent/ES2720763T3/en active Active
- 2013-06-27 WO PCT/US2013/048373 patent/WO2014004931A1/en not_active Ceased
- 2013-06-27 BR BR112014032728A patent/BR112014032728A2/en not_active IP Right Cessation
- 2013-06-27 US US13/929,723 patent/US20140038838A1/en not_active Abandoned
- 2013-06-27 KR KR1020157002289A patent/KR20150023904A/en not_active Ceased
- 2013-06-27 AU AU2013284448A patent/AU2013284448B2/en not_active Ceased
- 2013-06-27 NZ NZ703411A patent/NZ703411A/en not_active IP Right Cessation
- 2013-06-27 CN CN201380045178.1A patent/CN104583422A/en active Pending
- 2013-06-27 EP EP13809780.3A patent/EP2867375B1/en active Active
- 2013-06-27 EA EA201492284A patent/EA201492284A1/en unknown
- 2013-06-27 SG SG11201408651TA patent/SG11201408651TA/en unknown
- 2013-06-27 JP JP2015520541A patent/JP6352909B2/en not_active Expired - Fee Related
2014
- 2014-12-25 IL IL236482A patent/IL236482A0/en unknown
2016
- 2016-03-02 US US15/059,238 patent/US9797905B2/en active Active
2017
- 2017-09-15 US US15/706,105 patent/US20180031563A1/en not_active Abandoned
2018
- 2018-06-07 JP JP2018109092A patent/JP6581247B2/en not_active Expired - Fee Related

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004076614A2 (en) *	2003-02-27	2004-09-10	Bernd Hinzmann	Human nucleic acid sequences obtained from prostatic carcinomas
US20090215636A1 (en) *	2005-05-25	2009-08-27	Krizman David B	Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2007071947A1 (en) *	2005-12-19	2007-06-28	University Of Hull	Cancer screening test
WO2008121307A2 (en) *	2007-03-28	2008-10-09	Cell Genesys, Inc.	Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US20110236903A1 (en) *	2008-12-04	2011-09-29	Mcclelland Michael	Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2011040532A1 (en) *	2009-10-02	2011-04-07	学校法人久留米大学	Method for predicting therapeutic effect of immunotherapy on cancer patient and/or prognosis after immunotherapy, and gene set and kit to be used therein
EP2484762A1 (en) *	2009-10-02	2012-08-08	Kurume University	Method for predicting therapeutic effect of immunotherapy on cancer patient and/or prognosis after immunotherapy, and gene set and kit to be used therein
WO2011149402A2 (en) *	2010-05-27	2011-12-01	Atlas Antibodies Ab	Prostate cancer biomarkers
WO2012021969A1 (en) *	2010-08-16	2012-02-23	Mount Sinai Hospital	Markers of the male urogenital tract

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALAIYA: "Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 38, no. 4, 1 April 2011 (2011-04-01), GR, XP055236830, ISSN: 1019-6439, DOI: 10.3892/ijo.2011.937 *
CELESTIA S HIGANO ET AL: "Phase 1/2 Dose-Escalation Study of a GM-CSF- Secreting, Allogeneic, Cellular Immunotherapy for Metastatic Hormone-Refractory Prostate Cancer", CANCER, 1 January 2008 (2008-01-01), pages 975 - 984, XP055235903, Retrieved from the Internet <URL:http://deepblue.lib.umich.edu/bitstream/handle/2027.42/60980/23669_ftp.pdf?sequence=1> [retrieved on 20151211] *
D. ATANACKOVIC ET AL: "Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma", HAEMATOLOGICA, vol. 96, no. 10, 23 May 2011 (2011-05-23), pages 1512 - 1520, XP055039759, ISSN: 0390-6078, DOI: 10.3324/haematol.2010.036814 *
NIVEN R NARAIN ET AL: "Abstract 538: Identification and validation of novel prostate cancer biomarkers using the Berg Interrogative Biology(TM) platform", 1 August 2015 (2015-08-01), pages 538, XP055235900, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/75/15_Supplement/538.short> [retrieved on 20151211] *
RANGAPRASAD SARANGARAJAN ET AL: "Abstract 7: Berg Interrogative Biology (TM) platform unravels novel biomarkers FLNB and LY9 in combination with PSA enhances specificity in serum of patients with prostate cancer.", CANCER RESEARCH, vol. 73, no. 8 Supplement, 15 April 2013 (2013-04-15), US, pages 7 - 7, XP055264745, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2013-7 *
See also references of WO2014004931A1 *
TOBIAS-MACHADO MARCOS ET AL: "Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients.", TUMORI 2005 MAY-JUN, vol. 91, no. 3, May 2005 (2005-05-01), pages 248 - 252, XP008179862, ISSN: 0300-8916 *
ZACHAROULA PANTELEAKOU ET AL: "Detection of Circulating Tumor Cells in Prostate Cancer Patients: Methodological Pitfalls and Clinical Relevance", MOLECULAR MEDICINE, vol. 15, no. 3-4, 1 January 2009 (2009-01-01), pages 1, XP055172667, ISSN: 1076-1551, DOI: 10.2119/molmed.2008.00116 *

Also Published As

Publication number	Publication date
AU2013284448B2 (en)	2019-04-18
US20180031563A1 (en)	2018-02-01
NZ703411A (en)	2017-09-29
WO2014004931A1 (en)	2014-01-03
CA2877721A1 (en)	2014-01-03
BR112014032728A2 (en)	2017-11-28
JP6581247B2 (en)	2019-09-25
JP2015523569A (en)	2015-08-13
SG11201408651TA (en)	2015-01-29
US20140038838A1 (en)	2014-02-06
MX360236B (en)	2018-10-26
JP2018163164A (en)	2018-10-18
HK1209792A1 (en)	2016-04-08
CN104583422A (en)	2015-04-29
ES2720763T3 (en)	2019-07-24
EA201492284A1 (en)	2015-11-30
IL236482A0 (en)	2015-02-26
EP2867375B1 (en)	2019-02-27
KR20150023904A (en)	2015-03-05
MX2015000008A (en)	2015-04-10
US9797905B2 (en)	2017-10-24
JP6352909B2 (en)	2018-07-04
AU2013284448A1 (en)	2015-01-22
EP2867375A1 (en)	2015-05-06
US20160178632A1 (en)	2016-06-23

Legal Events

Date	Code	Title	Description
2015-04-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-05-06	17P	Request for examination filed	Effective date: 20150119
2015-05-06	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-05-06	AX	Request for extension of the european patent	Extension state: BA ME
2016-01-27	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/68 20060101ALI20151221BHEP Ipc: C12Q 1/68 20060101AFI20151221BHEP Ipc: G01N 33/574 20060101ALI20151221BHEP
2016-04-08	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1209792 Country of ref document: HK
2016-06-01	RA4	Supplementary search report drawn up and despatched (corrected)	Effective date: 20160503
2016-06-01	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/68 20060101ALI20160426BHEP Ipc: G01N 33/574 20060101ALI20160426BHEP Ipc: C12Q 1/68 20060101AFI20160426BHEP
2017-03-31	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-05-03	17Q	First examination report despatched	Effective date: 20170331
2018-02-05	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602013051529 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12Q0001680000 Ipc: G01N0033574000
2018-03-14	RIC1	Information provided on ipc code assigned before grant	Ipc: C12Q 1/6886 20180101ALI20180205BHEP Ipc: G01N 33/574 20060101AFI20180205BHEP
2018-04-05	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-04-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-05-02	INTG	Intention to grant announced	Effective date: 20180405
2018-08-08	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2018-08-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-09-12	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-09-12	INTC	Intention to grant announced (deleted)
2018-09-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-10-10	INTG	Intention to grant announced	Effective date: 20180913
2018-10-10	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: BERG LLC
2019-01-21	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2019-01-25	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2019-01-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2019-02-27	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-02-27	AX	Request for extension of the european patent	Extension state: BA ME
2019-02-27	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2019-02-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2019-03-14	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602013051529 Country of ref document: DE
2019-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1102128 Country of ref document: AT Kind code of ref document: T Effective date: 20190315
2019-03-20	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2019-07-03	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20190227
2019-07-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-07-24	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2720763 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190724
2019-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190527 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190627 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2019-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190527 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190627 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190528
2019-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1102128 Country of ref document: AT Kind code of ref document: T Effective date: 20190227
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2019-11-28	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602013051529 Country of ref document: DE
2019-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2019-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2020-01-03	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2020-01-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2020-01-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2020-02-05	26N	No opposition filed	Effective date: 20191128
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2020-03-27	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20190630
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2020-05-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190627
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190627 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630
2020-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20200625 Year of fee payment: 8 Ref country code: DE Payment date: 20200629 Year of fee payment: 8
2020-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20200629 Year of fee payment: 8 Ref country code: IT Payment date: 20200619 Year of fee payment: 8
2020-10-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20200701 Year of fee payment: 8
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130627 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2022-01-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602013051529 Country of ref document: DE
2022-02-23	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20210627
2022-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210627 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220101
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210630
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190227
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210627
2022-09-27	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20220927
2022-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210628
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230529

Publication	Publication Date	Title
EP2867375A4 (en)	2016-06-01	USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP2892558A4 (en)	2016-04-20	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2890815A4 (en)	2016-05-11	METHODS OF DIAGNOSIS AND TREATMENT OF CANCER
EP2882496A4 (en)	2016-07-06	TREATMENT AND DIAGNOSIS OF MELANOMA
EP2903597A4 (en)	2016-07-06	USE OF MICROVESICLES IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF DISEASES AND MEDICAL CONDITIONS
IL236664B (en)	2020-01-30	Monoclonal antibodies for use in the diagnosis and treatment of cancer and autoimmune diseases
EP2825889A4 (en)	2015-10-28	DIAGNOSIS OF ADENOVIRAL TUMOR
IL243408A0 (en)	2016-03-31	Diagnosis and treatment of cancer involving cancer stem cells
EP2780472A4 (en)	2015-10-28	METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BLADDER CANCER
EP2591363A4 (en)	2014-01-22	DIAGNOSIS AND TREATMENT OF BREAST CANCER
EP2968397A4 (en)	2016-12-28	DIAGNOSIS AND TREATMENT OF FIBROSIS
EP3307329A4 (en)	2019-05-15	TREATMENT AND DIAGNOSIS OF CANCER
EP2959291A4 (en)	2016-08-31	METHODS OF DIAGNOSING AND TREATING CANCER BY DETECTING AND HANDLING MICROBES IN TUMORS
EP2606349A4 (en)	2014-04-30	DIAGNOSIS OF CANCER AND ANTICANCER THERAPEUTIC AGENT
EP2723924A4 (en)	2015-03-25	METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
PL3085786T3 (en)	2026-02-16	The use of aptamers in the therapy and/or diagnosis of autoimmune diseases
EP2542155A4 (en)	2013-07-17	DIAGNOSIS OF CANCER AND IMAGING
SG10201605361RA (en)	2016-08-30	Slit-Robo Signaling for Diagnosis and Treatment of Kidney Disease
EP2861302A4 (en)	2016-08-24	USE OF CCR5 MODULATORS IN THE TREATMENT OF CANCER
EP2361317A4 (en)	2014-01-01	USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IL245936A0 (en)	2016-07-31	Methods for the treatment of blood cancer and the use of biomarkers as predictors of clinical sensitivity to immunomodulatory treatments
EP3303402A4 (en)	2019-05-01	ANTIBODIES AGAINST GLYPICAN-3 AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF CANCER
EP2948769A4 (en)	2016-11-09	PLATELET BIOMARKERS USED IN THE DIAGNOSIS OF CANCER
EP2922402A4 (en)	2016-11-09	DIAGNOSIS AND TREATMENT OF SMA AND SMN DEFICIT
EP2712649A4 (en)	2015-02-18	MEDICAL TREATMENT INSTRUMENT